You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
聯環藥業(600513.SH):阿奇黴素片通過仿製藥一致性評價
格隆匯 07-07 16:55

格隆匯7月7日丨聯環藥業(600513.SH)公佈,公司於近日收到國家藥品監督管理局核准簽發的關於阿奇黴素片《藥品補充申請批准通知書》,公司阿奇黴素片通過仿製藥質量和療效一致性評價。

阿奇黴素是大環內酯類抗生素亞類之一。主要用於治療流感嗜血桿菌、卡他莫拉菌或肺炎鏈球菌引起的慢性支氣管炎細菌感染急性發作,肺炎衣原體、流感嗜血桿菌、肺炎支原體或肺炎鏈球菌引起的社區獲得性肺炎等。

PDB藥物綜合數據庫顯示,2021年國內樣本醫院阿奇黴素片銷售額為2037.43萬元。2021年公司阿奇黴素片未銷售。

截至目前,公司阿奇黴素片一致性評價研發投入約為人民幣662.09萬元(未經審計)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account